Bring the immune system one step ahead of cancer

Unlocking the full potential of immuno-oncology by generating first-in-class immunotherapies to initiate a multi-specific in vivo immune response against tumors

THEY SUPPORT US

Inspired by patients, driven by science

At Brenus Pharma, we develop a new generation of treatments that will overcome limitations of classical immunotherapies and cell therapies— poor efficacy on cold tumors, manufacturing cost and supply issues— and improve the patient’s access to innovation

Mimicking cancer nature

Proprietary SGC off-the-shelf platform recapituling both the space and time heterogeneity of the tumor to generate first-in-class treatments

Operational excellence

A team of expert leaders and developpers of immuno oncology therapies backed by €30 million euro in funding

Scalable & cost efficient

A standardized and patented platform offering a limitless potential to address significant unmet needs by reducing cost and symplifying supplies

Solid tumors  

Fast growing needs, insufficient solutions 

of patient face 
therapeutic failure
0 %

leading to

every year worldwide
0 M deaths

The challenge

Cancer is a moving, heterogeneous & invisible target

Example of colorectal cancer (CRC): a cold tumor defined by heterogeneity, plasticity and treatment resistances

95% of patients (MSS type) have no other solution than outdated chemotherapies

5-year survival < 12%
2nd leading cause of cancer mortality worldwide

For these patients: the immune system, natural body’s defenser, is blinded

No immune reaction can be initiated toward tumor cells

Inefficiency 
of classical immunotherapy 

New therapeutic strategies are needed to restore anti-tumor immune response and capture cancer heterogeneity

Our solution:

Stimulated tumor Ghost Cells (SGC) technology

From “off-the-shelf” tumor banks to first-in-class immunotherapies 

Enriched with the molecular fingerprints of tumor heterogeneity and resistances.

Designed to safely unlock the immune system to fight back

1. Mimicking cancer plasticity with stimulated « off-the-shelf » tumor cell lines

Allogeneic cell lines selected to cover wide patient populations of the targeted indication

Stimulation by standards of care and physical shock to reveal + 200 cancer related proteins (CRP), linked to tumor specificity, plasticity and resistances mechanisms validated by proteogenomic and predictive model

2. Making it visible

Safely engage the immune system with haptenation and inactivation process (Ghost cell), enhancing recognition of proteins  by Antigen Presenting Cells (APCs) at in vivo level

DNFB HAPTEN

DINITROFLUOROBENZENE

CANCER RELATED PROTEINS

A unique value proposition for solid tumors

Anticipating tumor evolution from 1st line to overcome current limitations

SGC platform

Limitless potential to generate first-in-class immunotherapies

Reproducing in vivo tumor heterogeneity

> Using standards of care and physical shock

> Precision medicine applied to large patient populations

Neoantigens and cancer proteins validation

> Proteogenomic profiling matched with biopsies datasets

> Data science & deep learning prediction tools

Advanced antigens presentation methods 

> Fonctionnal validation by immunoassays

Standardized & Scalable manufacturing process

> GMP ready & specifically replicable to other solid tumors

> Platform & Product worldwide patented

STC-1010

CRC, PDAC, HCC

STC-1020

OVARIAN CANCER

STC-10XX

FUTURE DEVELOPMENT

Leveraging our SGC platform to generate strong candidates

product

UNMET NEED – WORLDWIDE

other indications

colorectal cancer

other indications

mCRC IL MSS: 95% of patients

2nd cause of cancer mortality

mCRC 2L MSI-H: 5% of patients

Combo: checkpoint inibitors

colorectal cancer

Pancreatic - PDAC

6th cause of cancer mortality

Liver disease - HCC

3rd cause of cancer mortality

ovarian cancer

ovarian cancer

STC-1020 + Adjuvant

5th cause of women cancer mortality

From vision to execution

€30M

Invested since 2020

2

Clinical candidates advancing toward IND filing by 2027

7

Clinical sites open in 2025
Phase I/II for colorectal cancer patients in 1L
(EU & US expansion planned)

100

patients treatable per batch
thanks to our standardized & scalable platform

2 388 000

Eligible patients by 2029

Our team

J.Gardette

Co-founder, president

B. Pinteur

Co-founder & CSO

P. Bravetti

CEO

C. Tortorelli

Sr Lead medical affairs

L. Chalus

Head of CMC Operations

D. Ezzedine

Board Member

Our team of 14 employees is driven by passion and dedication, working in collaboration to bring innovative therapeutic solutions to patients

A global scientific advisory board of renowned immuno-oncology experts, united for innovation

Pr A. EGGERMONT

MD, PhD.

PMC, Utrecht (NE) 
Former Gustave Roussy director 

Pr F. GHIRINGHELLI

MD, PhD.

CGFL,
Dijon

Pr O. J FINN

MD, PhD.

University of Pittsburgh, 
Pennsylvania

Pr M. YARCHOAN

MD, PhD.

Johns Hopkins University, 
Baltimore, Maryland

Pr I. MELERO

MD, PhD.

Academic Hospital 
& CIMA of Navarra 

Pr A. ITALIANO

MD, PhD.

Institut Bergonié, Bordeaux Gustave Roussy, Paris

Pr A. AWADA

MD, PhD.

Chirec Cancer Institute, 
Brussels

Pr J. TAIEB

MD, PhD.

Hospital Georges Pompidou,

Paris

Our investors

News and research

Brenus and InSphero Recreate Human Colorectal Cancer in 3D to Validate STC-1010’s Therapeutic Efficacy”

Brenus is proud to be part of the French Delegation at BIOUS 2025 Let’s connect and share insights

AACR 2025: Brenus Pharma presents late-breaking preclinical data of STC-1010

Supported by

Our awards

2024 AWARD BEST BIOTECH (FR)

2024 HEALTHCARE AWARD (FR)

2024 MOST PROMISING PROJECT AWARD (EU)

ALUMNI 2023 CANCER STREAM (CAN)

AWARD 2022 (USA)

ALUMNI 2022 (USA)

2022 NOMINATION BEST PHARMA STARTUP (USA)

2024 AWARD
BEST BIOTECH (FR)

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with broad & higher quality range of tumor antigens